Ensysce Biosciences reports Q1 GAAP EPS of -$0.52
Ensysce Biosciences reported a Q1 GAAP EPS of -$0.52, beating by $0.21.
The company received federal grants of $0.96M, a 27.3% year-over-year decrease, missing by $0.94M.
The company’s cash and cash equivalents were $0.7 million as of March 31, 2026, compared to $4.3 million as of December 31, 2025. On April 7, 2026, the company closed a second tranche of $2.0 million in convertible preferred stock financing under its previously announced November 2025 commitment for up to $20 million over 24 months.